Dactylis Glomerata Pollen

Dosage for Dactylis Glomerata Pollen is highly individualized and is not based on body weight, but rather on the patient's sensitivity level.

For Immunotherapy (SCIT)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 vol/vol dilution). Injections are usually given 1 to 2 times per week. The dose is gradually increased over 3 to 6 months until the maintenance dose is reached.
• Maintenance Phase: Once the effective dose is reached (often 0.5 mL of a 1:100 or 1:10 vol/vol concentration, or 1,000 to 4,000 BAU), the frequency of injections is decreased to once every 2 to 4 weeks. Maintenance therapy is generally continued for 3 to 5 years.

For Sublingual Tablets (SLIT)

• Standard Dose: Usually one tablet (e.g., 300 IR or equivalent BAU) daily. Treatment is often initiated 4 months before the expected start of the grass pollen season and continued throughout the season.

Dactylis Glomerata Pollen extracts are generally approved for use in children, typically starting at age 5 or 10, depending on the specific product and administration route.

• SCIT: Dosing follows the same build-up and maintenance principles as adults, though physicians may use more conservative escalations in highly sensitive children.
• SLIT: Specific 5-grass pollen tablets are FDA-approved for children and adolescents ages 10 through 17. The dosage is typically the same as the adult dose (one tablet daily).

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the protein components are not cleared by the kidneys in a manner that affects systemic toxicity. However, the patient's overall health must be stable to manage potential systemic reactions.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via local cellular pathways rather than hepatic CYP450 enzymes.

Elderly Patients

Caution is advised in elderly patients (over 65). While no specific dose reduction is mandated, the risk-benefit ratio must be carefully weighed. Elderly patients are more likely to have co-morbidities (like cardiovascular disease) that could make a systemic allergic reaction (anaphylaxis) more difficult to treat.

Subcutaneous Injections (SCIT)

• Must be administered in a clinical setting by a healthcare professional.
• Patients must remain in the office for at least 30 minutes following the injection to monitor for signs of anaphylaxis.
• The injection is given in the subcutaneous tissue of the upper arm.

Sublingual Tablets (SLIT)

• The first dose must be taken in a doctor's office under supervision.
• Subsequent doses are taken at home.
• Place the tablet under the tongue until it completely dissolves (usually within 1 minute). Do not swallow for at least one minute. Avoid eating or drinking for 5 minutes after administration.
• Store tablets in their original blister pack at room temperature (20°C to 25°C).

• SCIT: If an injection is missed, the next dose may need to be reduced depending on how much time has elapsed. If more than 4 weeks have passed since the last maintenance dose, the allergist will typically step back the dosage to ensure safety.
• SLIT: If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose. If multiple doses are missed, contact your physician before resuming.

An overdose of Dactylis Glomerata Pollen most commonly occurs during the build-up phase of SCIT or due to a calculation error. Signs of overdose are identical to a severe allergic reaction:

• Generalized hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid drop in blood pressure (shock)
• Nausea and abdominal cramping

Emergency Measures: In the event of an overdose or systemic reaction, Epinephrine (1:1000) must be administered intramuscularly immediately. Emergency medical services (911) should be contacted.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure you have an up-to-date Epinephrine auto-injector available at all times if you are undergoing immunotherapy.

Side effects are very common with Dactylis Glomerata Pollen because the treatment involves deliberate exposure to a known allergen.

• Local Injection Site Reactions (SCIT): Redness (erythema), itching (pruritus), and swelling (edema) at the site of the injection are expected. These usually appear within minutes and resolve within a few hours, though 'late-phase' swelling can occur 6-24 hours later.
• Oral Reactions (SLIT): Itching of the mouth (oral pruritus), throat irritation, and mild swelling of the tongue or lips are experienced by the majority of patients, especially during the first week of treatment. These symptoms typically diminish as the body desensitizes.

• Respiratory: Mild wheezing, cough, or a feeling of chest tightness. Nasal congestion and sneezing may also occur shortly after administration.
• Gastrointestinal: Nausea, abdominal pain, or 'itchy ears' (pruiritus of the external auditory canal).
• Dermatologic: Generalized itching or a few scattered hives away from the injection site.

• Eosinophilic Esophagitis (EoE): Specifically associated with sublingual forms, this is an inflammation of the esophagus characterized by difficulty swallowing (dysphagia) or chest pain.
• Severe Bronchospasm: A sudden, severe constriction of the airways, more common in patients with poorly controlled asthma.
• Vasovagal Reactions: Fainting or lightheadedness due to the injection process rather than the allergen itself.

> Warning: Stop taking Dactylis Glomerata Pollen and call your doctor immediately if you experience any of these symptoms of anaphylaxis:

• Angioedema: Severe swelling of the face, lips, tongue, or throat that may make breathing or swallowing difficult.
• Wheezing/Stridor: High-pitched breathing sounds or significant shortness of breath.
• Hypotension: A sudden feeling of weakness, dizziness, or passing out (signs of a drop in blood pressure).
• Tachycardia: A rapid, pounding heartbeat.
• Urticaria: Widespread, rapidly spreading hives and intense itching.
• Cyanosis: A bluish tint to the lips or fingernails, indicating lack of oxygen.

In general, Dactylis Glomerata Pollen immunotherapy is considered safe for long-term use (3-5 years).

• Immune System Changes: The primary long-term 'effect' is the desired modification of the immune system.
• Injection Site Fibrosis: Very rarely, repeated injections in the same area over years can lead to minor scarring or thickening of the subcutaneous tissue.
• EoE Progression: If sublingual therapy is continued despite symptoms of esophageal inflammation, chronic swallowing difficulties could develop.

Products containing Dactylis Glomerata Pollen for sublingual use (SLIT) and many injectable extracts carry an FDA Black Box Warning regarding Severe Allergic Reactions.

• Summary: Dactylis Glomerata Pollen can cause life-threatening allergic reactions such as anaphylaxis.
• Requirements: The first dose must be administered in a healthcare setting under the supervision of a physician prepared to manage anaphylaxis.
• Prescription Requirement: Patients must be prescribed and trained on the use of an auto-injectable epinephrine device (e.g., EpiPen) to keep with them at all times while on this medication.
• Contraindications: This treatment should not be used in patients with severe, unstable, or uncontrolled asthma.

Report any unusual symptoms to your healthcare provider. Even mild symptoms should be reported, as they may precede a more severe reaction during the next dose.

Dactylis Glomerata Pollen is a biological extract, not a standard pharmaceutical. Its use requires specialized medical oversight. The most critical safety consideration is the risk of a systemic allergic reaction. Patients must be in a stable state of health before receiving any dose. If you are feeling ill, having an asthma flare-up, or have sores in your mouth (for SLIT), you must notify your doctor before taking your dose, as these conditions increase the risk of a severe reaction.

No FDA black box warnings for Dactylis Glomerata Pollen (Standardized Injectable Extracts), however, Sublingual Tablets (SLIT) containing this pollen (like Oralair) DO carry a Black Box Warning.

Text Summary: 'Dactylis Glomerata Pollen extracts can cause life-threatening anaphylaxis and severe laryngospasm. Patients must be monitored for at least 30 minutes after the initial dose. Do not initiate in patients with unstable asthma or a history of severe systemic allergic reactions. Epinephrine must be available to the patient at all times.'

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Anaphylaxis can occur at any time during treatment, even if previous doses were well-tolerated. It is most common during the build-up phase.
• Asthma Status: Patients with asthma must have their condition well-controlled (e.g., FEV1 > 80% of predicted) before receiving immunotherapy. An asthma 'attack' during immunotherapy can be fatal.
• Eosinophilic Esophagitis: For patients using sublingual forms, any new or worsening difficulty swallowing or persistent heartburn must be reported, as this may indicate the development of EoE.
• Oral Surgery/Lesions: For sublingual use, treatment should be paused if there are open sores in the mouth, following dental surgery, or after losing a tooth (in children), as this provides a direct route for the allergen into the bloodstream.

• Observation Period: A mandatory 30-minute wait in the clinic after every injection.
• Lung Function Tests: Periodic spirometry or peak flow monitoring may be required for asthmatic patients.
• Skin Testing: Periodic re-evaluation of skin sensitivity may be performed to assess the progress of the treatment.
• Symptom Logs: Patients are often asked to keep a diary of local and systemic reactions to guide dosage adjustments.

Dactylis Glomerata Pollen generally does not affect the ability to drive or operate machinery. However, if a patient experiences a systemic reaction, dizziness, or receives antihistamines/epinephrine for a reaction, they should not drive until fully recovered.

There is no direct chemical interaction between alcohol and Dactylis Glomerata Pollen. However, alcohol consumption can increase peripheral vasodilation, which may theoretically accelerate the absorption of the allergen or worsen the symptoms of an allergic reaction. It is best to avoid alcohol for several hours after a dose.

• Tapering: Tapering is not required for Dactylis Glomerata Pollen. You can stop the medication at any time.
• Loss of Efficacy: If treatment is stopped prematurely (before 3 years), the allergic symptoms are likely to return during the next pollen season.
• Withdrawal: There is no withdrawal syndrome associated with this biological extract.

> Important: Discuss all your medical conditions with your healthcare provider before starting Dactylis Glomerata Pollen, especially any history of heart disease or severe asthma.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated in patients receiving Dactylis Glomerata Pollen immunotherapy. Beta-blockers can increase the severity of an anaphylactic reaction and, more critically, they block the effects of Epinephrine, making the standard rescue treatment for anaphylaxis ineffective.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications may increase the risk of severe systemic reactions or worsen the hypotension (low blood pressure) associated with anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the body's ability to process adrenaline (epinephrine), potentially leading to unpredictable responses during the treatment of a systemic reaction.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these may potentiate the effects of epinephrine used in emergencies, requiring careful monitoring.

• Other Immunotherapy: If you are receiving 'allergy shots' for other substances (like dust mites or mold), the timing must be coordinated to avoid an 'overload' of the immune system.
• Antihistamines (e.g., Cetirizine, Loratadine): While often used to manage side effects, antihistamines can mask the early warning signs of a systemic reaction (like itching or hives), potentially delaying the recognition of anaphylaxis.
• Systemic Corticosteroids: Long-term use of prednisone or other steroids may suppress the immune response, potentially making the immunotherapy less effective.

• Oral Allergy Syndrome (OAS): Patients allergic to Dactylis Glomerata Pollen may experience cross-reactivity with certain foods (like peaches, tomatoes, or melons). Consuming these foods around the time of a dose may increase oral itching.
• High-Fat Meals: There is no evidence that food affects the absorption of sublingual Dactylis Glomerata Pollen, but it is recommended to take the dose on an empty stomach (or at least 5 minutes before eating) to ensure optimal mucosal contact.

• Immune Stimulants (e.g., Echinacea, Astragalus): These supplements could theoretically interfere with the desensitization process, although clinical data is lacking.
• St. John's Wort: While primarily a CYP3A4 inducer, its effects on the overall immune milieu are not well-studied in the context of AIT.

• Skin Prick Tests: Dactylis Glomerata Pollen treatment will eventually decrease the size of the 'wheal and flare' reaction on future skin tests. This is not an interaction but a sign of clinical efficacy.
• Specific IgE Blood Tests (ImmunoCAP): Treatment may cause an initial rise in specific IgE followed by a long-term decline. It will also significantly increase specific IgG4 levels.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting drug levels). The clinical consequence is an increased risk of untreated anaphylaxis. The management strategy is typically to switch the patient to alternative non-interfering medications (e.g., switching a beta-blocker to a calcium channel blocker) before starting immunotherapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure or heart conditions.

Conditions where Dactylis Glomerata Pollen must NEVER be used include:

1. 1Severe or Uncontrolled Asthma: Patients with an FEV1 < 80% of predicted or those with frequent exacerbations are at an unacceptably high risk of fatal bronchospasm during a systemic reaction.
2. 2History of Severe Systemic Allergic Reaction: If a patient has previously had a life-threatening reaction to grass pollen extracts, the risk of re-challenge often outweighs the benefit.
3. 3Eosinophilic Esophagitis (for SLIT): Patients with a pre-existing diagnosis of EoE should not use sublingual forms, as it can exacerbate the underlying esophageal inflammation.
4. 4Hypersensitivity to Excipients: Some preparations contain inactive ingredients (like gelatin or lactose) that a patient might be allergic to.
5. 5Inability to Use Epinephrine: Patients who, for physical or psychological reasons, cannot or will not use an epinephrine auto-injector are not candidates for home-based SLIT.

Conditions requiring careful risk-benefit analysis:

• Autoimmune Diseases: There is a theoretical risk that immunotherapy could flare an underlying autoimmune condition (like Lupus or Rheumatoid Arthritis), though evidence is limited.
• Malignancy: Patients with active cancer are generally not started on immunotherapy to avoid complicating their primary treatment.
• Beta-Blocker Therapy: As noted in interactions, this is a significant relative contraindication due to the interference with epinephrine.
• Active Oral Infections: For SLIT, things like gingivitis or oral candidiasis (thrush) should be treated before starting therapy.

Patients allergic to Dactylis Glomerata Pollen almost always show cross-sensitivity to other grasses in the subfamily Pooideae, including:

• Timothy Grass (Phleum pratense)
• Kentucky Bluegrass (Poa pratensis)
• Perennial Rye Grass (Lolium perenne)
• Sweet Vernal Grass (Anthoxanthum odoratum)

This cross-sensitivity is due to highly conserved proteins (Group 1 and Group 5 allergens) shared across these species. If a patient is allergic to one, they are likely allergic to all, and treatment with a standardized extract of one may provide some 'coverage' for the others.

> Important: Your healthcare provider will evaluate your complete medical history and perform a physical exam before prescribing Dactylis Glomerata Pollen.

FDA Pregnancy Category: B or C (depending on the specific manufacturer).

• Risk Summary: There are no adequate and well-controlled studies of Dactylis Glomerata Pollen in pregnant women. However, it is generally accepted in the allergy community that immunotherapy should not be initiated during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is usually continued at that dose, as the risk of a reaction is lower once maintenance is reached.
• Teratogenicity: There is no evidence that allergenic extracts are teratogenic (cause birth defects).

It is not known whether Dactylis Glomerata Pollen allergens or the resulting antibodies pass into breast milk. However, because these are naturally occurring proteins and the systemic concentration is negligible, the risk to the nursing infant is considered extremely low. The decision to continue immunotherapy while breastfeeding should be a shared decision between the mother and her doctor.

• Approval: SCIT is used in children as young as 5 years old. SLIT tablets (like Oralair) are approved for children 10 years of age and older.
• Growth Effects: There is no evidence that immunotherapy affects growth or development. In fact, some studies suggest that early immunotherapy can prevent the 'allergic march'—the progression from hay fever to asthma.
• Considerations: Children must be mature enough to communicate if they are feeling the early symptoms of a reaction.

• Safety: Patients over 65 are at higher risk of complications from anaphylaxis. The stress of a systemic reaction can trigger a myocardial infarction (heart attack) or arrhythmia in patients with underlying heart disease.
• Pharmacokinetics: No changes in the processing of the allergen occur, but the physiological 'reserve' to handle a reaction is diminished.

There are no specific studies in patients with renal impairment. However, since the clearance of these proteins is not dependent on the kidneys, no dose adjustment is expected. The clinician should ensure the patient is stable enough to tolerate emergency medications if needed.

Similarly, hepatic impairment does not affect the metabolism of Dactylis Glomerata Pollen. No dose adjustments are required. The primary concern would be the patient's overall metabolic stability and ability to handle the stress of a potential systemic reaction.

> Important: Special populations require individualized medical assessment and often more frequent monitoring during the build-up phase of treatment.

Dactylis Glomerata Pollen acts as an immunomodulator. The primary molecular targets are the T-lymphocytes and B-lymphocytes.

1. 1Early Phase: Immunotherapy induces the production of IL-10 and TGF-β by regulatory T-cells. These cytokines suppress Th2 cells.
2. 2Late Phase: B-cells are signaled to switch production from IgE to IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody.
3. 3Effector Cell Changes: Over months, the number of mast cells and eosinophils in the nasal and conjunctival mucosa decreases, and their threshold for activation increases.

• Dose-Response: There is a clear dose-response relationship in immunotherapy. Doses that are too low are ineffective, while doses that are too high increase the risk of systemic reactions. The 'optimal' dose is the highest dose the patient can tolerate without a systemic reaction.
• Onset of Effect: Clinical improvement is not immediate. It typically takes 3 to 6 months to notice a reduction in symptoms, with maximal benefit occurring after 1 to 2 years of continuous treatment.
• Duration of Effect: One of the unique aspects of this treatment is the 'carry-over' effect. After a full 3-5 year course, many patients remain symptom-free for several years after stopping the medication.

| Parameter | Value |

|---|---|

| Bioavailability | Low (systemically); High (locally in mucosa) |

| Protein Binding | N/A (Proteins are degraded, not bound to albumin) |

| Half-life | Minutes to hours (for the proteins themselves) |

| Tmax | 0.5 - 2 hours (for peak mucosal uptake) |

| Metabolism | Proteolytic degradation by immune cells |

| Excretion | Cellular turnover products |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides. The major allergens in Dactylis Glomerata are designated as Dac g 1 (a beta-expansin) and Dac g 5 (a ribonuclease-family protein).
• Molecular Weight: Ranges from 10 kDa to 70 kDa for the primary allergenic proteins.
• Solubility: Highly soluble in aqueous solutions and phosphate-buffered saline.

Dactylis Glomerata Pollen is classified as an Allergenic Extract. It is part of the therapeutic class of Immunosuppressives/Immunomodulators used for desensitization. It is closely related to other grass pollen extracts like Phleum pratense (Timothy Grass).